The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Influence of the Angiotensin II Antagonist Valsartan on Left Ventricular Hypertrophy in Patients With Essential Hypertension
Open accessAbstract
Background —Left ventricular hypertrophy (LVH) represents an independent risk factor in patients with essential hypertension. Because reversal of LVH may be associated with an improvement of prognosis, the influence of new antihypertensive compounds, such as angiotensin II AT 1 receptor antagonists, on LVH should be determined. Methods and Results —In a randomized, double-blind trial, 69 predominantly previously untreated hypertensive patients with echocardiographically proven LVH, ie, left ventricular mass index (LVMI) >134 g/m 2 in men and >110 g/m 2 in women and/or end-diastolic septal thickness >12 mm, received either the angiotensin II antagonist valsartan or atenolol for 8 months. Echocardiographic data of 58 patients were available. After 8 months of valsartan treatment (n=29), LVMI decreased from 127±23 to 106±25 g/m 2 (ratio [ R ]=0.83; 95% CI, 0.79 to 0.87; P <0.0001 versus baseline). Under atenolol (n=29), LVMI decreased to a smaller extent, from 127±25 to 117±27 g/m 2 ( R =0.92; 95% CI, 0.86 to 0.98; P =0.0082 versus baseline). The mean reduction of LVMI came to 21 g/m 2 under valsartan and only to 10 g/m 2 under atenolol ( R =0.91; 90% CI, 0.85 to 0.97 versus atenolol). Baseline mean blood pressure values were determined to be 163±12/101±6 mm Hg before treatment with valsartan and 160±14/103±6 mm Hg before atenolol treatment. After 8 months of treatment, mean blood pressure decreased to 146±13/90±7 mm Hg with valsartan and to 147±18/90±7 mm Hg with atenolol. Nine patients in the valsartan group and 8 patients in the atenolol group required additional medication with hydrochlorothiazide. Conclusions —Antihypertensive treatment with the angiotensin II antagonist valsartan for 8 months produced a significant regression of LVH in predominantly previously untreated patients with essential hypertension. The drug may be safely administered in this subset of hypertensive patients; however, the long-term benefit in terms of risk reduction has still to be evaluated in further trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222203 · Cited by 5,699
Mancia, G., Zanchetti, A., Agebiti-Rosei, E., Benemio, G., De Cesaris, R., Fogari, R., Pessino, A., Porcellati, C., Salvetti, A., & Trimarco, B. (1997) · Circulation · doi:10.1161/01.cir.95.6.1464 · Cited by 596
Cited by
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,824
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Authors/Task Force Members:, Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehm236 · Cited by 2,384
International Union of Pharmacology. XXIII. The Angiotensin II Receptors
de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W., & Unger, T. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01458-3 · Cited by 2,132
A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension
Klingbeil, A. U., Schneider, M., Martus, P., Messerli, F. H., & Schmieder, R. E. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00158-x · Cited by 761
Metadata
- Authors
- Thürmann, P. A., Kenedi, P., Schmidt, A., Harder, S., & Rietbrock, N.
- Venue
- Circulation
- Published
- 1998-11-10
- Volume
- 98
- Issue
- 19
- Pages
- 2037-2042
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2093934591
- Cited by
- 196
- References
- 2
- FWCI
- 14.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Influence of the Angiotensin II Antagonist Valsartan on Left Ventricular Hypertrophy in Patients With Essential Hypertension. https://app.cochat.ai/papers/10.1161/01.cir.98.19.2037
- The paper
- Thürmann, P. A., Kenedi, P., Schmidt, A., Harder, S., & Rietbrock, N. (1998). Influence of the Angiotensin II Antagonist Valsartan on Left Ventricular Hypertrophy in Patients With Essential Hypertension. Circulation. https://doi.org/10.1161/01.cir.98.19.2037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.